The Vaccines and Related Biological Products Advisory Committee of the Food and Drug Administration voted to confer emergency use authorization for Moderna’s COVID-19 vaccine. Twenty members of the committee voted in favor of the EUA and one abstained. (STAT)

Residents of U.S. nursing homes are beginning to receive the Pfizer/BioNTech vaccine as the increasing numbers of COVID-19 cases continue to set new records. The nationwide infection rate is now estimated to be 11%. (Fox News)

The U.S. government is reportedly in negotiations with Pfizer to purchase additional doses of the company’s COVID-19 vaccine. Health and Human Services Secretary Alex Azar attempted to reassure Americans that contracts with other vaccine producers, including Moderna, will be sufficient to meet demand. (Associated Press) 

A new prostate cancer screening method has been approved by the Food and Drug Administration. Cancer specialists believe the test, which uses a radioactive tag to locate prostate cancer cells throughout subjects’ bodies, may revolutionize screening. (The New York Times)

GlaxoSmithKline has reached a $815 million deal with Surface Oncology for licensing rights to its lead cancer drug, SRF813. The inclusion of a “natural killer approach” is seen as complementing GSK’s other T-cell/adaptive immunity programs. (Endpoints News